BROMOCRIPTINE MESYLATE Drug Patent Profile
✉ Email this page to a colleague
When do Bromocriptine Mesylate patents expire, and what generic alternatives are available?
Bromocriptine Mesylate is a drug marketed by Lek Pharm, Mylan, Zydus Pharms Usa Inc, Aurobindo Pharma Usa, Padagis Us, and Sandoz. and is included in six NDAs.
The generic ingredient in BROMOCRIPTINE MESYLATE is bromocriptine mesylate. There are nine drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the bromocriptine mesylate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Bromocriptine Mesylate
A generic version of BROMOCRIPTINE MESYLATE was approved as bromocriptine mesylate by SANDOZ on January 13th, 1998.
Summary for BROMOCRIPTINE MESYLATE
US Patents: | 0 |
Applicants: | 6 |
NDAs: | 6 |
Finished Product Suppliers / Packagers: | 6 |
Raw Ingredient (Bulk) Api Vendors: | 53 |
Clinical Trials: | 6 |
Patent Applications: | 3,275 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for BROMOCRIPTINE MESYLATE |
What excipients (inactive ingredients) are in BROMOCRIPTINE MESYLATE? | BROMOCRIPTINE MESYLATE excipients list |
DailyMed Link: | BROMOCRIPTINE MESYLATE at DailyMed |
Recent Clinical Trials for BROMOCRIPTINE MESYLATE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Case Western Reserve University | Phase 1/Phase 2 |
Andrew Moshfeghi, MD, MBA | Phase 1/Phase 2 |
VeroScience | Phase 1 |
Pharmacology for BROMOCRIPTINE MESYLATE
Drug Class | Ergot Derivative |